Health conditions like insulin resistance and high blood pressure may complicate the journey
Nutritional priorities to support GLP-1 therapy for obesity
Chung, DO, MA from Beacon Therapeutics, as well as Huma Q
The small number of outcome events in this study, which recorded only 70 events among 25,617 users of GLP-1RAs and had only 6,622 patients on GLP-1RAs remaining two years after cohort entry, has limited statistical power
This conservative approach maintains the option to pause or discontinue if complications arise, while keeping treatment affordable and accessible across all 50 states without insurance requirements
We do not have a monthly membership fee